Thyroid Disorders
Read Time: 12 mins

An Update on Alopecia and its Association With Thyroid Autoimmune Diseases

Copy Link
Published Online: Aug 10th 2023 touchREVIEWS in Endocrinology. 2023;19(2):54-59 DOI:
Authors: Doaa Aboalola, Sihem Aouabdi, Majed Ramadan, Tariq Alghamdi, Mona Alsolami, Dalal Malibari, Rawiah Alsiary
Quick Links:
Article Information

Alopecia is comorbid with several illnesses, including various autoimmune conditions such as thyroid disease. Leukocyte-mediated inflammation of hair follicles in alopecia was first described over a century ago. However, the high prevalence of the role of thyroid autoimmune disease in the pathogenesis of alopecia has only recently come to light, together with a strong association between the two. Therefore, this review focuses on articles published between 2011 and 2022 on alopecia’s association with thyroid autoimmune disease, and the mechanism behind it. In addition, it highlights the link between alopecia and thyroid cancer, as patients with alopecia have increased risk of thyroid cancer. In conclusion, this comprehensive, focused, scoping review will serve as a reference highlighting recent information on alopecia, exploring its association with thyroid autoimmune diseases.


Alopeciaautoimmune thyroiditisfocused reviewthyroid cancerthyroid autoimmune diseases and alopeciathyroid cancer and alopecia.


Alopecia is a dermatological disorder characterized by hair loss from the scalp or body.1–3 It is one of the most common dermatological disorders worldwide and has several aetiologies, such as hereditary background, hormonal imbalance, infection or idiopathic causes.1,3,4 Alopecia can be classified into two main categories: scarring (or cicatricial) alopecia and non-scarring (non-cicatricial) alopecia (Figure 1).1–3

Scarring alopecia is a complex and heterogeneous group of hair disorders resulting in irreversible destruction of the hair follicle, which is then replaced by fibrous scar tissue, due to permanent follicular stem cell damage.1–3 Non-scarring alopecia is caused by an alteration in the capillary cycle, which causes temporary or partial damage to hair follicles, resulting in hair shedding followed by hair regrowth.1,3

This comprehensive, focused review aims to serve as an up-to-date reference highlighting recent information on alopecia and its association with thyroid autoimmune diseases (TADs), focusing on case-control, retrospective, cross-sectional or cohort designs, and focused review articles published between 2011 and 2022.

Scarring alopecia

Primary cicatricial alopecia, often termed scarring alopecia, describes a group of hair loss disorders in which the hair follicle is permanently destroyed and replaced by fibrous tissue.1–3,5–7 Most types of primary scarring alopecia, some of which overlap or occur simultaneously, are classified as inflammatory skin disorders.8 Primary scarring alopecia is less common than non-scarring alopecia, representing about 5–7% of cases.3,6 With scarring alopecia, the skin is bald, smooth and shiny inside the patches, and pores are absent due to a complete loss of follicular openings.6

The hypotheses proposed to explain why scarring alopecia occurs include the loss of follicular immune privilege, alterations in the microbiota of the local pilosebaceous unit, abnormal lipid metabolism, the possible involvement of mast cells and an association with skin care products and sunscreens.8–11 The role of genetics in scarring alopecia also remains unclear.8,9

Scarring alopecia is further subdivided into lymphocytic, neutrophilic and multiple causes (Figure 1).1,3

Lymphocytic primary scarring alopecia

Discoid lupus erythematosus

Discoid lupus erythematosus can occur in the absence of any systemic disease or in conjunction with systemic lupus erythematosus.9,12–14 It is known to progress with exposure to sunlight (ultraviolet light), so it mainly affects the scalp, face and ears, causing scarring alopecia and facial disfigurement.6,12–14 The clinical features of discoid lupus erythematosus include alopecia characterized by well-defined, coin-shaped persistent erythematous indurated plaques of varying size, followed by follicular hyperkeratosis, which is skin adherent.5,9,12–14 When the adhering scale is removed, follicle-sized keratotic spikes like carpet tacks can be observed (“carpet tack sign”).5,9,12–14 The lesions slowly extend with active inflammation and hyperpigmentation at the periphery, resulting in depressed central atrophy, scarring, telangiectasia and hypopigmentation. Discoid lupus erythematosus can lead to permanent scarring alopecia on the scalp.5,9,12–14

Keratosis follicularis spinulosa decalvans

Keratosis follicularis spinulosa decalvans is a rare genetic disorder that often starts in infancy or early childhood and predominantly affects males.9,15–18 It presents with progressive scarring alopecia of the scalp and eyebrows.9,15–18

Lichen planopilaris

Lichen planopilaris is characterized by a lymphocytic invasion of hair follicles and is common in women between the ages of 40 and 60.19–21 Patients with lichen planopilaris may experience itching, burning or tenderness of the scalp.19,20

Frontal fibrosing alopecia

Frontal fibrosing alopecia is an irreversible chronic lymphocytic scarring alopecia; its cause is unknown.22,23 It is distinguished by progressive regression of the frontal and temporal hairlines, usually associated with loss of eyebrows and eyelashes.9,22–24

Alopecia mucinosa

Alopecia mucinosa refers to permanent hair loss that occurs when hair follicles are replaced by mucin.7,9,25 Clinically, it presents as erythematous-infiltrated plaques with follicular prominence, especially in the head and neck.25

Central centrifugal scarring alopecia

Central centrifugal scarring alopecia (CCSA) typically manifests as irreversible hair loss on the crown of the scalp and progresses in a centrifugal pattern to the parietal scalp.5,9,26,27 The exact cause of CCSA is unknown and considered to be multifactorial. A gene variant was recently discovered in approximately 25% of patients with CCSA; however, the exact role of this variant in the occurrence of CCSA is unclear.26–28

Pseudopelade of Brocq

Pseudopelade of Brocq is a rare, chronic and gradually progressive form of scarring alopecia that mainly affects middle-aged women.8,29 The vertex and parietal scalp are commonly involved, and it is distinguished by the clinical appearance of small skin-coloured alopecia patches that look similar to “footprints in the snow”, and mild-to-moderate atrophy with no evidence of folliculitis or significant inflammation.7–9,29

Neutrophilic primary scarring alopecia

Dissecting cellulitis of the scalp, or Hoffman’s disease

Dissecting cellulitis of the scalp, or Hoffman’s disease, is a rare form of neutrophilic alopecia of unknown aetiology that leads to irreversible hair loss.30–32 The clinical features of dissecting cellulitis of the scalp are nodules, abscesses on the vertex and posterior scalp, draining sinuses and scarring alopecia.30–32

Folliculitis decalvans

Folliculitis decalvans is the most common type of neutrophilic alopecia.33–35 It is characterized by painful follicular pustules that expand centrifugally, erosions and scaly-crusty lesions localized in the scalp, which leave central scarring and hair loss.33–35 Folliculitis decalvans typically affects only the scalp; however, one report has mentioned the involvement of the limbs and trunk.34

Mixed primary scarring alopecia

Acne keloidalis nuchae

Acne keloidalis nuchae is a chronic inflammatory form of scarring folliculitis.36–40 The clinical features are the occurrence of keloid-like papules, pustules and plaques; it most commonly affects the occipital scalp and posterior neck.36,39 The exact aetiology of acne keloidalis nuchae is unclear. However, this condition may be caused by chronic mechanical irritation to the back of the neck and scalp, trauma, heat, humidity, infection, autoimmune disorder, medications, and excess of some hormones such as androgens.36–38 Treatment, which aims to improve the symptoms of the disease, is difficult and unsatisfactory; many treatments have been tried with varying degrees of success.38

Acne necrotica

Acne necrotica is a bizarre and enigmatic rare follicular disorder that manifests as a necrotizing disorder of the hair follicle.7,9,40 It is characterized by the development of papules on the scalp with central necrosis in adult patients and causes pox-like scars.7,9 It represents a diagnostic challenge due to its distinct clinical pathological features.40

Erosive pustular dermatosis of the scalp

Erosive pustular dermatosis of the scalp is a rare chronic inflammatory skin disease that causes scarring alopecia and mainly affects older adults.41–43 The condition is commonly found on the scalp or legs but can occur anywhere on the skin.41 Clinical diagnosis may be difficult because it is similar to more common diseases, such as squamous cell carcinoma, infection, localized scarring pemphigoid (the Brunsting-Perry type), or folliculitis decalvans, and has non-specific clinical characteristics (crusts, atrophy, and pustules).41–43

Non-scarring alopecia

Non-scarring alopecia, also called non-cicatricial alopecia, refers to recoverable hair loss.1,3,44 It is classified into androgenetic alopecia (AGA), telogen effluvium (TE), traction alopecia, trichotillomania and alopecia areata (AA) (Figure 1).1,3,44

Androgenetic alopecia

AGA, often called male pattern baldness, is an autosomal dominant disorder that gradually transforms terminal hairs into intermediate and vellus hairs.45–47 It is the most common progressive baldness in both men and women; however, clinical symptoms differ between genders. In men, AGA causes gradual thinning and vertex loss; in women, hair loss affects the frontal scalp and vertex, while the frontal hairline is spared, resulting in a more visible scalp.45,47 Testosterone metabolite and dihydrotestosterone are the most important mediators of AGA. They act on androgen receptors in the hair follicles, causing hair thinning in the anagen phase and extending the telogen phase of hair growth, leading to more immature hair and decreasing the new hair.45–47 Some studies linked AGA to systemic diseases such as metabolic syndrome, endocrine diseases, mental disorders and hypothyroidism.45,46 The treatment for AGA consists of oral finasteride, topical external use of minoxidil, low-intensity laser and hair transplantation; however, whether the treatments are successful remains controversial.45–47

Telogen effluvium

TE is a common non-scarring alopecia that mainly affects women.47–50 It consists of diffuse hair loss occurring 2–3 months after a triggering event and lasting about 6 months; this hair loss leads to an abnormal shift of scalp hair follicles from anagen to telogen, resulting in premature hair shedding.47–49 TE can be caused by low ferritin, vitamin B12 deficiency, thyroid dysfunctions, systemic diseases, drugs, medications, fever, stress, weight loss and giving birth.47–50

Traction alopecia

Traction alopecia occurs in individuals who have hairstyles that exert a consistent pulling force on the hair roots.51,52 It is most common in women of African descent, who may braid their hair tightly and use chemical treatments to straighten it.51,52 In the early stages, patients with traction alopecia usually present with patches of non-scarring hair loss and tensioned areas of the scalp; in its later stages, the disease can progress to irreversible scarring alopecia if left untreated.51 Patients may also report tenderness, itching and headaches.51


Trichotillomania is a psychiatric condition classified as an obsessive–compulsive disorder, in which a person pulls out hair from any part of their body regularly, resulting in hair loss.53–55 It can affect any part of the body; however, it most commonly affects the scalp, followed by the eyebrows and the pubic region.53–55 Clinically, it appears as patches of varying size and shape; however, the patches are not completely bald but are covered in an irregular pattern of broken hair.47

Alopecia areata

AA is the most frequent cause of inflammation-induced, immune-mediated non-scarring hair loss disorder.56–58 It has an unpredictable course and a broad spectrum of manifestations (Figure 1).

Although it is uncommon in children under 3 years, the vast majority of patients with AA are young. Up to 66% of patients are under 30, and only 20% of patients are older than 40.56–62 AA is characterized by a rapid onset, with patients experiencing hair loss in well-circumscribed patches, usually round or oval in shape, and entirely hairless and smooth.56,58,59,61 In 90% of clinical diagnoses, AA’s most common clinical feature is a circumscribed area of bald skin on the scalp that is usually isolated from other patches.57,58,60 Since AA is a dynamic disorder (i.e. causing recurrent episodes of hair loss), patches may appear in other parts of the body, such as the elbows, arms and thighs.60 Furthermore, the disease may affect facial hair, including eyelashes, eyebrows and the beard area.60 One of the factors that may influence the onset of AA is stress.47,57,62–65 Some patients reported an emotional event or an identity crisis prior to the onset of AA.47,57,62–65 Other factors, such as infections, toxins, genetic factors and even food, could be triggers of the disease. AA is often associated with other diseases, such as systemic lupus erythematosus, autoimmune haemolytic anaemia, asthma, atopic dermatitis, vitiligo, allergic rhinitis, and thyroid diseases.47,57,62–65

Thyroid autoimmune diseases and alopecia

Several known TADs cause hypothyroidism (e.g. Hashimoto’s thyroiditis [HT], painless thyroiditis and postpartum thyroiditis), hyperthyroidism (e.g. Graves’ disease [GD]), or subacute thyroiditis (e.g. De Quervain thyroiditis).66 The most common TADs are GD and HT.67 TADs, which are also marked by autoantibodies targeting thyroid follicular cells, are the most common autoimmune disease associated with alopecia.68

HT is the most common cause of autoimmune hypothyroidism.67,69 Women are more affected by HT than men, with a ratio of 18:1; however, men are increasingly affected by this pathology.70 One of the most common clinical signs of HT is alopecia.68–70 GD is the most common hyperthyroidism, resulting from the hyperstimulation of the thyroid gland due to the presence of thyrotropin receptor antibodies that bind and activate the thyroid-stimulating hormone receptor, increasing synthesis of triiodothyronine (T3) and the prohormone thyroxine (T4).71 GD is an autoimmune disease associated with AA.72,73 Thyroid hormones are involved in hair growth, and alopecia affecting different areas of the body is one of the clinical signs of thyroid dysfunction.74 The presence of alopecia and thyroid dysfunction increases with age.74 Moreover, androgenic alopecia, the most common form of alopecia affecting men and women of all ages, is strongly correlated with autoimmune thyroiditis, especially hypothyroidism.75–78 Due to the high prevalence of hair loss and thyroid dysfunction, exploring the thyroid function is recommended in patients with alopecia.79

It was reported that more than 42.7% of patients with AA express thyroid autoantibodies such as anti-thyrotropin receptor antibodies, suggesting that anti-thyroid and anti-hair follicle autoimmunity share a similar aetiology.72 Furthermore, the prevalence of thyroid antibodies was found to be significantly associated with AA.80,81 Genetic variability between some populations might also affect the frequency of TAD. The frequency of AA varies geographically; for instance, in the Korean population, thyroid diseases, including hyperthyroidism, hypothyroidism, goitre and thyroiditis, were the most common in late-onset AA.82

AA is an autoimmune disease that targets the hair follicles by T cell-mediated autoimmune reaction.83,84 The aetiology of AA is not well understood; however, it is strongly associated with thyroid dysfunction such as HT.85 Several studies showed a high prevalence of thyroid autoimmunity (GD and HT and various thyroid disorders) associated with AA.80–85 A 3-year retrospective study by Chen et al. also found a high prevalence of AA in TAD.86 The occurrence of thyroid diseases such as HT, endemic goitre and GD in patients with AA ranges between 8% and 28%.87 AA is mostly associated with GD and with the presence of thyrotropin receptor antibodies.72

Alopecia is associated with other autoimmune diseases, such as vitiligo, coeliac disease, diabetes mellitus, psoriasis and lupus erythematous.88 It may also be associated with genetic predisposition and stress.89 Stress can increase P (SP)-immunoreactive nerve fibres, leading to mast degranulation and activation of pro-inflammatory cytokines and chemokines in the thyroid gland.83,90 Similarly to TAD, alopecia was found to have an hereditary component: it was linked significantly to human leukocyte antigen Class II alleles DR4, DR11, DPw4, DQw3, DQw7, and DQw8 and to HLA Class I alleles A28, B12, B13, B18, and B27.87 AA shares a similar mechanism with TAD, characterized by the involvement of the CD8+ and CD4+ T cells targeting hair follicle auto-antigens resulting in cytokines production.88 Cytokine interferon (IFN-) is the most important factor produced in AA via CD4+ Th1-mediated response.83 The pro-inflammatory cytokine interleukin-1 (IL-1) recruits inflammatory cells such as T-lymphocytes, neutrophils and macrophages to the affected tissue. Together with tumour necrosis factor (TNF)-alpha, they suppress hair growth.91 TNF, together with other Th1 cytokines (IFN, IL-2 and IL-12), are increased in lesion biopsies of patients with AA, with TNF being the most important factor.92 The lesion is inflammation induced and reversible as it causes a non-scaring loss of hair follicles.90 Moreover, the infiltration of hair follicles by the T lymphocytes results in the release of other factors, such as TNFs and enzymes, causing apoptosis of the cells in the hair follicle.93

The link between thyroid hormones and hair follicles

Insight into the hair growth process reveals that every single hair on the scalp passes through four stages: the anagen phase, in which the hair grows from the follicle; the catagen phase, in which the follicle shrinks, and the hair detaches from the scalp; the telogen phase, in which a new hair begins to grow underneath the old hair; and the exogen phase, wherein the old hair falls off and is replaced by the new hair.94 As part of this process, old hairs at the end of their growth cycle constantly fall out from the scalp, causing the loss of approximately 50100 hairs per day. However, since the hair follicles do not all grow synchronously, a daily loss does not impact the physical appearance.94 Understanding this simple mechanism is crucial to understanding how thyroid disorders can affect the induction of alopecia and chronic hair loss.

The structure and function of the hair and skin can certainly be impacted by low or high levels of thyroid hormones, such as the active hormone T3 and the prohormone T4, the main product of the thyroid gland.95 However, the specific mechanism by which T3/T4 stimulation affects human hair follicles, and whether an increase or decrease in T3 and/or T4 levels directly influences the development of alopecia, are yet to be known. Thyroid hormones play a crucial role in regulating myriads of cellular functions, including growth, differentiation, metabolism and thermogenesis.95,96 Hence, disruption of the production of thyroid hormones, especially T3 and T4 hormones, can affect many essential bodily processes, including the healthy growth of hair. Thyroid hormones may contribute to hair loss by interfering with the body’s normal hair development cycle. If the thyroid function is damaged, the hair might not grow as fast as it normally would, so when old hairs get to the end of their hair growth cycle, new ones do not sufficiently replace them. Hence, thyroid disorders cause alopecia. As the evidence indicates, both T3 and T4 sustain the length of the hair development phase (anagen) in vitro, which might be the result of the downregulation of the important anagen-inhibitory growth factor (TGF-2) by thyroid hormones.95,96

As hair growth is a highly energy-consuming process,97 Vidal et al. hypothesized that thyroid hormones promote mitochondrial function and regulate human energy metabolism in hair follicles, which leads to an increase in the expression of some mitochondrial genes and proteins that regulate intra-follicular mitochondrial energy metabolism and the redox status of human hair follicles.97,98 The results of these studies collectively indicated that thyroid hormones directly target hair follicles and dramatically affect their biology. Therefore, hair loss can occur when these hormones are produced abnormally. However, the molecular mechanisms have not yet been fully understood. Both thyrotropin-releasing hormone and its receptor are expressed in the human scalp hair follicles.99 As a result, it is possible that the hypothalamic–pituitary–thyroid pathway exists outside of the hair follicles in humans.

Thyroid cancer and alopecia

The first study to describe alopecia following thyroid cancer therapy was published in 1998.100 The authors believed that the amount of radiation exposure to hair follicles is much below the level required to result in hair loss. Therefore, the temporary, non-dose-dependent occurrence of hair loss cannot be a result of the radioiodine therapy, and it is most likely the outcome of thyroid hormone status changes due to thyroid cancer.

Thyroid hormone receptors, which are crucial for controlling the hair’s growth cycle, have been found in hair follicles.101 Moreover, the assumption that thyroid cancer causes alopecia and vice versa is based on hormone involvement in AA and on the fact that some thyroid diseases are linked to alopecia.102 It has been shown that Taiwanese women suffering from alopecia are more likely to develop thyroid cancer than those without alopecia.103 While structural thyroid abnormalities did not appear to be associated specifically with any type of alopecia,104 the risk of thyroid cancer is increased based on the alopecia subtype.105 A previous study of 12,199 patients with AA found that a significant increase in the risk of thyroid cancer was observed in patients with AA; however, a significant decrease was noted in the risk of other types of cancers, such as breast, colon/rectum, stomach, liver and lung cancer.106 Moreover, it is hypothesized that alopecia might inhibit carcinogenesis due to its immunological and genetic similarities to multiple sclerosis, whose innate immune profile (characterized by increased T helper type 1 immune activation and altered cytokine levels) reduces the risk of developing cancer.107 In addition, the correlation between alopecia and thyroid cancer was investigated and proved in the presence of two TADs (GD and HT).103,108–112 Moreover, patients with AA were found to be at greater risk of TAD,113 and alopecia was found to be significantly associated with thyroid cancer.113–115 A recently published study in Cancer Epidemiology described a 26-year-old female patient who was diagnosed with thyroid cancer 8 years before developing alopecia.116

Except for thyroid cancer, which is more common in people with alopecia, the correlations between solid organ tumour cancers and alopecia have been negligible.116,117


In this focused review of articles published between 2011 and 2022, we showed that alopecia is correlated with TAD and thyroid cancer.

Thyroid hormones contribute to hair loss by interfering with the normal cycle of hair development; if the thyroid function is damaged, the hair takes longer and requires more energy to regrow. Therefore, alopecia is an effect of thyroid disorders. However, the specific mechanism by which the production of thyroid hormones, especially T3 and T4 hormones, affects human hair follicles and the development of alopecia, is still unknown.94–96

Moreover, hypothyroidism, in which the thyroid gland does not produce enough thyroid hormones, or hyperthyroidism, in which the thyroid gland produces excess thyroxine hormone, often result from autoimmune conditions. Many of these patients have a higher risk of developing autoimmune conditions such as alopecia, which causes patches of hair loss in discrete areas leading to baldness. With that established, it is easier to see why thyroid conditions can cause alopecia.66–79 AA is an autoimmune disease targeting the hair follicles through a T cell-mediated autoimmune reaction that is strongly correlated with thyroid dysfunction.83–85 The exact cause of alopecia is not well known, but AA is strongly associated with TAD.80–85

Similarly, thyroid cancer and alopecia have been significantly associated. The direct action of thyroid hormone has physiological effects on the scalp and hair follicles resulting in alopecia.107,113–115 Although a significant correlation between thyroid cancer and TAD was found in patients with alopecia, the relationship is mostly negligible and needs to be investigated further.

In conclusion, the literature demonstrates complete understanding of alopecia and its types. However, more studies are required to fully understand the mechanism and association between TAD and alopecia, as well as between alopecia and thyroid cancer.

Article Information:

Doaa Aboalola, Sihem Aouabdi, Majed Ramadan, Tariq Alghamdi, Mona Alsolami, Dalal Malibari and Rawiah Alsiary have no financial or non-financial relationships or activities to declare in relation to this article.

Compliance With Ethics

This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.

Review Process

Double-blind peer review.


The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.


Rawiah AlsiaryKing Abdullah International Medical Research Center – Western Region (KAIMRC-WR), King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard – Health Affairs, PO BOX 9515Jeddah 21423Saudi


No funding was received in the publication of this article.


This article is freely accessible at © Touch Medical Media 2023

Data Availability

All data generated or analysed during this study are included in this published article/as supplementary information files.




1. Hashmi AARashid KAli Ret alClinicopathological features of alopecia with an emphasis on etiology and histopathological characteristics of scarring alopecia. Cureus. 2022;14:e27661. DOI: 10.7759/cureus.27661.

2. Lin JSaknite IValdebran Met alFeature characterization of scarring and non-scarring types of alopecia by multiphoton microscopy. Lasers Surg Med. 2019;51:95103. DOI: 10.1002/lsm.23017.

3. Cardoso COTolentino SGratieri Tet alTopical treatment for scarring and non-scarring alopecia: An overview of the current evidenceClin Cosmet Investig Dermatol. 2021;14:48599DOI10.2147/CCID.S284435.

4. Salim SKamalasanan KControlled drug delivery for Alopecia: A reviewJ Control Release. 2020;325:8499. DOI: 10.1016/j.jconrel.2020.06.019.

5. Rongioletti FChristana KCicatricial (scarring) alopecias: An overview of pathogenesis, classification, diagnosis, and treatmentAm J Clin Dermatol. 2012;13:24760. DOI: 10.2165/11596960-000000000-00000.

6. Filbrandt RRufaut NJones LSinclair RPrimary cicatricial alopecia: Diagnosis and treatment. CMAJ. 2013;185:157985. DOI: 10.1503/cmaj.111570.

7. Bernárdez CMolina-Ruiz AMRequena LHistologic features of alopecias: Part II: Scarring alopeciasActas Dermosifiliogr. 2015;106:26070. DOI: 10.1016/

8. Sundberg JPHordinsky MKBergfeld Wet alProgress towards the diagnosis, treatment and cure of primary cicatricial alopecias. Cicatricial Alopecia Research Foundation meeting. 2018;27:30210. DOI: 10.1111/exd.13495.

9. Hordinsky MScarring alopecia: Diagnosis and new treatment options. Dermatol Clin. 2021;39:3838. DOI: 10.1016/j.det.2021.05.001.

10. Kreuter ALicciardi-Fernandez MJBurmann S-Net alBaricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia. Clin Exp Dermatol. 2022;47:7878. DOI: 10.1111/ced.15044.

11. Jimenez FHarries MPoblet EFrontal fibrosing alopecia: A disease fascinating for the researcher, disappointing for the clinician and distressing for the patientExp Dermatol. 2016;25:8534DOI10.1111/exd.13104.

12. McDaniel BSukumaran SKoritala TTanner LSDiscoid lupus erythematosusInStatPearls [Internet]Treasure Island (FL)StatPearls Publishing2022.

13. Drenkard CParker SAspey LDet alRacial disparities in the incidence of primary chronic cutaneous lupus erythematosus in the southeastern US: The Georgia Lupus RegistryArthritis Care Res2019;71:95103. DOI: 10.1002/acr.23578.

14. Salah EClinical and dermoscopic spectrum of discoid lupus erythematosus: Novel observations from lips and oral mucosaInt J Dermatol2018;57:8306DOI: 10.1111/ijd.14015.

15. Verma RBhatnagar AVasudevan BKumar SKeratosis follicularis spinulosa decalvansIndian J Dermatol Venereol Leprol2016;82:2146DOI10.4103/0378-6323.173590.

16. Sanke SMendiratta VSingh AChander RKeratosis follicularis spinulosa decalvans with associated mental retardation: Response to isotretinoinInt J Trichology. 2017;9:1389DOI10.4103/ijt.ijt_25_17.

17. Eckl KMGruber RBrennan Let alCystatin M/E variant causes autosomal dominant keratosis follicularis spinulosa decalvans by dysregulating cathepsins L and VFront Genet2021;12:689940DOI10.3389/fgene.2021.689940.

18. Bhoyrul BSinclair RSuccessful treatment of keratosis follicularis spinulosa decalvans with an 800-nm diode laserDermatol Surg2020;46:84950DOI: 10.1097/DSS.0000000000001892.

19. Naeini FFSaber MFaghihi GLichen planopilaris: A review of evaluation methodsIndian J Dermatol Venereol Leprol2021;87:4425DOI10.25259/IJDVL_775_18.

20. Svigos KYin LFried Let alA practical approach to the diagnosis and management of classic lichen planopilaris. Am J Clin Dermatol. 2021;22:68192. DOI: 10.1007/s40257-021-00630-7.

21. Babahosseini HTavakolpour SMahmoudi Het al. Lichen planopilaris: Retrospective study on the characteristics and treatment of 291 patients. J Dermatolog Treat. 2019;30:598604. DOI: 10.1080/09546634.2018.1542480.

22. Aldoori NDobson KHolden CRet alFrontal fibrosing alopecia: Possible association with leave-on facial skin care products and sunscreens; A questionnaire study. Br J Dermatol. 2016;175:7627DOI10.1111/bjd.14535.

23. Robinson GMcMichael AWang SQLim HWSunscreen and frontal fibrosing alopecia: A reviewJ Am Acad Dermatol2020;82:7238DOI: 10.1016/j.jaad.2019.09.085.

24. Kerkemeyer KLSEisman SBhoyrul Bet al. Frontal fibrosing alopecia. Clin Dermatol2021;39:18393DOI: 10.1016/j.clindermatol.2020.10.007.

25. Khalil JKurban MAbbas OFollicular mucinosis: A review. Int J Dermatol. 2021;60:15965. DOI: 10.1111/ijd.15165.

26. Ezekwe NKing MHollinger JCThe use of natural ingredients in the treatment of alopecias with an emphasis on central centrifugal cicatricial alopecia: A systematic review. J Clin Aesthet Dermatol2020;13:237.

27. Aguh CMcMichael ACentral centrifugal cicatricial alopeciaJAMA Dermatol2020;156:1036DOI: 10.1001/jamadermatol.2020.1859.

28. Lawson CNBakayoko ACallender VDCentral centrifugal cicatricial alopecia: Challenges and treatments. Dermatol Clin. 2021;39:389405. DOI: 10.1016/j.det.2021.03.004.

29. Nair PASinghal RPariath KPrimary idiopathic pseudopelade of Brocq in a young child. Int J Trichology. 2017;9:1135. DOI: 10.4103/ijt.ijt_24_17.

30. De Bedout VHarper HMiteva MLev-Tov H. Treatment dissecting cellulitis of the scalp with secukinumabJ Drugs Dermatol. 2021;20:7767. DOI: 10.36849/JDD.5615.

31. Sung K-YLee SJeong YLee S-YDissecting cellulitis of the scalp: A diagnostic challenge. Arch Plast Surg. 2020;47:6312. DOI: 10.5999/aps.2020.00633.

32. Cuellar TARoh DSSampson CEDissecting cellulitis of the scalp: A review and case studies of surgical reconstruction. Plast Reconstr Surg Glob Open. 2020;8:e3015. DOI: 10.1097/GOX.0000000000003015.

33. Rambhia PHConic RRZMurad Aet alUpdates in therapeutics for folliculitis decalvans: A systematic review with evidence-based analysis. J Am Acad Dermatol. 2019;80:794801. DOI: 10.1016/j.jaad.2018.07.050.

34. Senatore SMaglie RMaio Vet alFolliculitis decalvans with exclusive beard involvement. Indian J Dermatol Venereol Leprol. 2021;87:56971. DOI: 10.25259/IJDVL_694_20.

35. Miguel-Gómez LRodrigues-Barata ARMolina-Ruiz Aet alFolliculitis decalvans: Effectiveness of therapies and prognostic factors in a multicenter series of 60 patients with long-term follow-upJ Am Acad Dermatol2018;79:87883DOI10.1016/j.jaad.2018.05.1240.

36. Brahe CPeters KMeunier NAcne keloidalis nuchae in the armed forcesCutis2020;105:2236.

37. Al Aboud DMBadriTAcne Keloidalis NuchaeInStatPearls [Internet]Treasure Island (FL)StatPearls Publishing2022.

38. Ogunbiyi AAcne keloidalis nuchae: Prevalence, impact, and management challengesClin Cosmet Investig Dermatol2016;9:4839DOI10.2147/CCID.S99225.

39. Pitney LKO’Brien BPitney MJAcne necrotica (necrotizing lymphocytic folliculitis): An enigmatic and under-recognised dermatosisAustralas J Dermatol. 2018;59:e538DOI10.1111/ajd.12592.

40. Barrera-Godínez AOliveros-Hernández AFGatica-Torres Met alAcne necrotica in a woman with systemic lupus erythematosus and systemic sclerosis. Cureus. 2022;14:e23008DOI10.7759/cureus.23008.

41. Piccolo VRusso TBianco Set alErosive pustular dermatosis of the scalp: Why do we miss it? Dermatology. 2019;235:3905DOI10.1159/000500909.

42. Wilk MZelger BGHauser Uet alErosive pustular dermatosis of the scalp: Reappraisal of an underrecognized entity. J Dtsch Dermatol Ges. 2018;16:159. DOI: 10.1111/ddg.13387.

43. Leem SWKim MKKo SLet alLiterature review on Korean medicine treatment for alopecia. J Pharmacopuncture. 2021;24:93106. DOI: 10.3831/KPI.2021.24.3.93.

44. Nestor MSAblon GGade Aet alTreatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20:375981. DOI: 10.1111/jocd.14537.

45. Chen SXie XZhang GZhang YComorbidities in androgenetic alopecia: A comprehensive reviewDermatol Ther (Heidelb)2022;12:223347DOI10.1007/s13555-022-00799-7.

46. Alessandrini ABruni FPiraccini BMStarace MCommon causes of hair loss – clinical manifestations, trichoscopy and therapy. J Eur Acad Dermatol Venereol. 2021;35:62940. DOI: 10.1111/jdv.17079.

47. Cheng TFang HWang Yet alThe diagnostic value of serum ferritin for telogen effluvium: A cross-sectional comparative studyClin Cosmet Investig Dermatol.  2021;14:13741DOI10.2147/CCID.S291170.

48. Grace SASutton AMAbraham Net alPresence of mast cells and mast cell degranulation in scalp biopsies of telogen effluviumInt J Trichology2017;9:259DOI: 10.4103/ijt.ijt_43_16.

49. Asghar FShamim NFarooque Uet al. Telogen effluvium: A review of the literatureCureus. 2020;12:e8320. DOI10.7759/cureus.8320.

50. Billero VMiteva MTraction alopecia: The root of the problem. Clin Cosmet Investig Dermatol. 2018;11:14959. DOI: 10.2147/CCID.S137296.

51. Pulickal JKAlopecia KFTTraction Alopecia. In: Statpearls [Internet]. Treasure Island (FL): Statpearls publishing, 2022.

52. Neal-Barnett AStatom DStadulis RTrichotillomania symptoms in African American women: Are they related to anxiety and culture? CNS Neurosci Ther. 2011;17:20713. DOI: 10.1111/j.1755-5949.2010.00138.x.

53. Grant JEChamberlain SRTrichotillomania. Am J Psychiatry. 2016;173:86874. DOI: 10.1176/appi.ajp.2016.15111432.

54. Pereyra ADSaadabadi ATrichotillomaniaInStatPearls [Internet]Treasure Island (FL)StatPearls Publishing, 2023. Available at:

55. Franklin MEZagrabbe KBenavides KLTrichotillomania and its treatment: A review and recommendationsExpert Rev Neurother2011;11:116574DOI: 10.1586/ern.11.93.

56. Rajabi FDrake LASenna MMRezaei NAlopecia areata: A review of disease pathogenesis. Br J Dermatol. 2018;179:103348DOI10.1111/bjd.16808.

57. Villasante Fricke ACMiteva MEpidemiology and burden of alopecia areata: A systematic reviewClin Cosmet Investig Dermatol2015;8:397403DOI: 10.2147/CCID.S53985.

58. Rencz FGulácsi LPéntek Met alAlopecia areata and health-related quality of life: A systematic review and meta-analysisBr J Dermatol2016;175:56171DOI: 10.1111/bjd.14497.

59. Strazzulla LCWang EHCAvila Let alAlopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesisJ Am Acad Dermatol. 2018;78:112DOI10.1016/j.jaad.2017.04.1141.

60. Trüeb RMDias MFRGAlopecia areata: A comprehensive review of pathogenesis and managementClin Rev Allergy Immunol2018;54:6887DOI10.1007/s12016-017-8620-9.

61. Renert-Yuval YGuttman-Yassky EThe changing landscape of alopecia areata: The therapeutic paradigmAdv Ther2017;34:1594609DOI10.1007/s12325-017-0542-7.

62. Uzuncakmak TKEngin BSerdaroglu STuzun YDemographic and clinical features of 1,641 patients with alopecia areata, alopecia totalis, and alopecia universalis: A single-center retrospective study. Skin Appendage Disord. 2021;7:812. DOI: 10.1159/000510880.

63. Liu LYKing BACraiglow BGHealth-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. J Am Acad Dermatol. 2016;75:80612. DOI: 10.1016/j.jaad.2016.04.035.

64. Juárez-Rendón KJReyes-López Rivera Sánchez Get alAlopecia areata. Current situation and perspectives. Arch Argent Pediatr. 2017;115:e40411. DOI: 10.5546/aap.2017.eng.e404.

65. Sterkens ALambert JBervoets AAlopecia areata: A review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med. 2021;21:21530. DOI: 10.1007/s10238-020-00673-w.

66. Anaya JMShoenfeld YRojas-Villarraga Aet alAutoimmunity: From Bench to Bedside [Internet]Bogota (Colombia)El Rosario University Press2013.

67. Stathatos NDaniels GHAutoimmune thyroid disease. Curr Opin Rheumatol. 2012;24:705DOI: 10.1097/BOR.0b013e32834ddb27.

68. Eschler DCHasham ATomer YCutting edge: The etiology of autoimmune thyroid diseasesClin Rev Allergy Immunol2011;41:1907DOI10.1007/s12016-010-8245-8.

69. Caturegli PDe Remigis ARose NRHashimoto thyroiditis: Clinical and diagnostic criteriaAutoimmun Rev2014;13:3917DOI10.1016/j.autrev.2014.01.007.

70. Ajjan RAWeetman APThe pathogenesis of Hashimoto’s thyroiditis: Further developments in our understanding. Horm Metab Res. 2015;47:70210. DOI: 10.1055/s-0035-1548832.

71. De Luca RDavis PJLin H-Yet alThyroid hormones interaction with immune response, inflammation and non-thyroidal illness syndromeFront Cell Dev Biol. 2020;8:614030DOI10.3389/fcell.2020.614030.

72. Taketomo YNoso SBabaya Net alCommon phenotype and different non-HLA genes in Graves’ disease and alopecia areataHum Immunol2017;78:1859DOI: 10.1016/j.humimm.2016.10.019.

73. Aşık MBinnetoğlu EŞen Het alGraves’ disease associated with alopecia areata developing after Hashimoto’s thyroiditisJ Nippon Med Sch2013;80:4679DOI: 10.1272/jnms.80.467.

74. Vincent MYogiraj KA descriptive study of alopecia patterns and their relation to thyroid dysfunctionInt J Trichology2013;5:5760DOI10.4103/0974-7753.114701.

75. Bosnić ZŠarić BVučić Det alAlopecia in preexisting autoimmune thyroid disease in family medicine practice: Can hyperprolactinemia induce hair loss? A case report. Acta Dermatovenerol Alp Pannonica Adriat. 2021;30:757. DOI: 10.15570/actaapa.2021.18.

76. Lolli FPallotti FRossi Aet alAndrogenetic alopecia: A review. Endocrine. 2017;57:917. DOI: 10.1007/s12020-017-1280-y.

77. Krysiak RKowalcze KOkopień BThe impact of exogenous vitamin D on thyroid autoimmunity in euthyroid men with autoimmune thyroiditis and early-onset androgenic alopeciaPharmacol Rep2021;73:143947DOI: 10.1007/s43440-021-00295-3.

78. Siah TWMuir-Green LShapiro JFemale pattern hair loss: A retrospective study in a tertiary referral centerInt J Trichology2016;8:5761DOI10.4103/0974-7753.188033.

79. Babaei KKavoussi HRezaei MKavoussi R. Characteristics of telogen effluvium in COVID-19 in Western Iran (2020)An Bras Dermatol2021;96:68892DOI: 10.1016/j.abd.2021.05.006.

80. Díaz-Angulo SLópez-Hoyos MMuñoz-Cacho Pet alHigh prevalence of thyroid autoimmunity in patients with alopecia areata and vitiligo: A controlled study. Australas J Dermatol. 2015;56:1423. DOI: 10.1111/ajd.12321.

81. Saylam Kurtipek GCihan FGErayman Demirbaş Ş, Ataseven A. The frequency of autoimmune thyroid disease in alopecia areata and vitiligo patients. Biomed Res Int. 2015;2015:435947. DOI: 10.1155/2015/435947.

82. Lee NRKim B-KYoon NYet alDifferences in comorbidity profiles between early-onset and late-onset alopecia areata patients: A retrospective study of 871 Korean patientsAnn Dermatol2014;26:7226DOI: 10.5021/ad.2014.26.6.722.

83. Abd Elshafy RAKhalifa NABesher RMAbdel Mawla MYMAlopecia areata: An overview of the disease and its genetic basis. The Egyptian Journal of Hospital Medicine. 2022;88:2897903. DOI: 10.21608/ejhm.2022.242771.

84. Bin Saif GASevere subtype of alopecia areata is highly associated with thyroid autoimmunity. Saudi Med J. 2016;37:65661. DOI: 10.15537/Smj.2016.6.13777.

85. Lee SLee YBKim BJLee WSScreening of thyroid function and autoantibodies in patients with alopecia areata: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;80:14103. DOI: 10.1016/j.jaad.2018.10.066.

86. Chen CHWang KHLin HCChung SDFollow-up study on the relationship between alopecia areata and risk of autoimmune diseases. J Dermatol. 2016;43:2289. DOI: 10.1111/1346-8138.13165.

87. Alkhalifah AAlsantali AWang Eet alAlopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62:17788. DOI: 10.1016/j.jaad.2009.10.032.

88. Gilhar AEtzioni APaus RAlopecia areataN Engl J Med2012;366:151525DOI10.1056/NEJMra1103442.

89. Huang KPMullangi SGuo YQureshi AAAutoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol. 2013;149:78994. DOI: 10.1001/jamadermatol.2013.3049.

90. Naik PPFarrukh SNAssociation between alopecia areata and thyroid dysfunction. Postgrad Med. 2021;133:8958. DOI: 10.1080/00325481.2021.1974689.

91. Philpott MPSanders DABowen JKealey TEffects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: A possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areataBr J Dermatol1996;135:9428DOI10.1046/j.1365-2133.1996.d01-1099.x.

92. Gregoriou SPapafragkaki DKontochristopoulos Get alCytokines and other mediators in alopecia areata. Mediators Inflamm. 2010;2010:928030. DOI: 10.1155/2010/928030.

93. Wang EMcElwee KJEtiopathogenesis of alopecia areata: Why do our patients get it? Dermatol Ther. 2011;24:33747. DOI: 10.1111/j.1529-8019.2011.01416.x.

94. Zhang BTsai P-CGonzalez-Celeiro Met alHair follicles’ transit-amplifying cells govern concurrent dermal adipocyte production through Sonic Hedgehog. Genes Dev. 2016;30:232538. DOI: 10.1101/gad.285429.116.

95. Paus RA neuroendocrinological perspective on human hair follicle pigmentation. Pigment Cell Melanoma Res. 2011;24:89106. DOI: 10.1111/j.1755-148X.2010.00808.x.

96. Horesh EJChéret JPaus RGrowth hormone and the human hair follicle. Int J Mol Sci. 2021;22:13205. DOI: 10.3390/ijms222413205.

97. Vidali SKnuever JLerchner Jet alHypothalamic–pituitary–thyroid axis hormones stimulate mitochondrial function and biogenesis in human hair folliclesJ Invest Dermatol2014;134:3342DOI10.1038/jid.2013.286.

98. Arrojo E Drigo RBianco ACType 2 deiodinase at the crossroads of thyroid hormone actionInt J Biochem Cell Biol2011;43:143241DOI: 10.1016/j.biocel.2011.05.016.

99. Gáspár ENguyen-Thi KTHardenbicker Cet al. Thyrotropin-releasing hormone selectively stimulates human hair follicle pigmentation. J Invest Dermatol. 2011;131:236877. DOI: 10.1038/jid.2011.221.

100. Alexander CBader JBSchaefer Aet alIntermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinomaJ Nucl Med1998;39:15514.

101. Islam NLeung PSCHuntley ACGershwin METhe autoimmune basis of alopecia areata: A comprehensive review. Autoimmun Rev. 2015;14:819. DOI: 10.1016/j.autrev.2014.10.014.

102. Sun L-MLin M-CMuo C-Het alWomen with alopecia exhibit a higher risk for thyroid cancer: A nationwide cohort studyJ Dermatol Sci2014;74:1822DOI: 10.1016/j.jdermsci.2013.12.005.

103. Lo Sicco KMcGuire SEnglish JCA retrospective study of thyroid structural abnormalities in alopecia patients. Dermatoendocrinol. 2011;3:2514. DOI: 10.4161/derm.3.4.16838.

104. Lee JHSong YDo Han Ket alCancer risk by the subtype of alopecia. Sci Rep. 2018;8:9748. DOI: 10.1038/s41598-018-28142-1.

105. Wicaksana AComorbid autoimmune diseases and cancer risks among patients with alopecia areata: A population-based case-control study in KoreaJ Am Acad Dermatol. 2018;79:AB80DOI10.1016/j.jaad.2018.05.354.

106. Seo HMHan SSKim JSCancer risks among patients with alopecia areata: A population-based case-control study in KoreaJ Am Acad Dermatol2018;78:20911. DOI: 10.1016/j.jaad.2017.08.011.

107. Franks ALSlansky JEMultiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancerAnticancer Res. 2012;32:111936.

108. Chen Y-KLin C-LChang Y-Jet alCancer risk in patients with Graves’ disease: A nationwide cohort study. Thyroid. 2013;23:87984. DOI: 10.1089/thy.2012.0568.

109. Kim KWPark YJKim EHet alElevated risk of papillary thyroid cancer in Korean patients with Hashimoto’s thyroiditisHead Neck2011;33:6915DOI: 10.1002/hed.21518.

110. Lun YWu XXia Qet alHashimoto’s thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg. 2013;148:396402. DOI: 10.1177/0194599812472426.

111. Han TYLee JHNoh TKet alAlopecia areata and overt thyroid diseases: A nationwide population-based studyJ Dermatol2018;45:14117DOI10.1111/1346-8138.14648.

112. You HRKim S-JFactors associated with severity of alopecia areataAnn Dermatol2017;29:56570DOI: 10.5021/ad.2017.29.5.565.

113. Conic RZRambhia PAtanaskova-Mesinkovska Net alLack of an association between alopecia areata and visceral or hematopoietic cancers. J Am Acad Dermatol. 2017;77:9812. DOI: 10.1016/j.jaad.2017.06.045.

114. Bertolini MGilhar APaus RAlopecia areata as a model for T cell-dependent autoimmune diseases. Exp Dermatol. 2012;21:4779. DOI: 10.1111/j.1600-0625.2011.01427.x.

115. Wollina UAndrogenetic Alopecia and thyroid cancer: Coincidence or more? InClinical Cases in Hair Disorders. Cham: Springer International Publishing, 2022;957. DOI: 10.1007/978-3-030-93423-1.

116. Mostaghimi AQureshi SJoyce Cet alReduced incidence of skin cancer in patients with alopecia areata: A retrospective cohort study. Cancer Epidemiol. 2016;41:12931. DOI: 10.1016/j.canep.2016.02.009.

117. Lee SLee HLee CHLee WSComorbidities in alopecia areata: A systematic review and meta-analysisJ Am Acad Dermatol2019;80:46677DOI: 10.1016/j.jaad.2018.07.013.

Further Resources

Share this Article
Related Content In Thyroid Disorders
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72